Our Science : Drug Discovery Platforms : Compound Archives
At FORMA, the compounds in our library are part of a continuously evolving collection that is refined and enhanced by data generated in our ongoing discovery programs. FORMA owns a proprietary collection of diverse, chemically pure, drug-like molecules for our high-throughput screening initiatives. In addition to the molecules that are produced to support of each particular target or target family (focused libraries), the library consists of distinct series of compounds. Structural novelty and drug-like properties are key drivers for including compounds in the collection, and their designs are assisted by in silico evaluation of a broad variety of physical and biological parameters. The series of compounds in our collection are:
The Diversity Compound Collection was designed to be distinct from commercially available libraries and to provide optimal starting points for drug optimization. Although in aggregate, commercial compounds generally have a relatively high number of aromatic and/or heteroaromatic rings with sp2 character, the FORMA libraries contain complex compounds with greater sp3 character. This aids our ability to expand chemical space using a limited number of synthetic, refunctionalization, and deprotection steps and to maintain compatibility with our parallel synthesis platform.
The Diversity Oriented Synthesis (DOS) Collection combines the stereochemical richness and structural diversity akin to natural products with the ease of synthesis in combinatorial chemistry. The DOS library of approximately 160,000 single molecules explores the complete stereochemical space of 14 chiral scaffolds, which each contain two to five asymmetric carbon atoms, making our collection the largest, most complex, and purest one of its kind. Over 500 chiral scaffolds were created to start the functionalization processes for the scaffolds.
FORMA’s Shape-Directed Library contains drug-like and structurally diverse molecules that have unique properties based on our CS-Map structure-based drug discovery platform, covering the nearly 17,000 human protein structures in the protein database. Several basic shapes associated with druggable “hot spots” are defined by geometric considerations, such as bond angles and ring systems, and by stereoelectronic factors that drive conformational bias. With upward of 50 scaffolds for each basic shape library and over 1,000 exemplars for each scaffold, a substantial number of novel molecules readily expands our compound collection.
Typically, our collection compounds are produced in sufficient quantities for rapid follow-up of confirmed screening hits. This infrastructure investment has enabled us to reduce typical follow-up times several-fold.
Solution Phase Parallel Synthesis and Purification